Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125319251 | 12531925 | 1 | I | 20160629 | 20160706 | 20160706 | EXP | US-PFIZER INC-2016325294 | PFIZER | 0.00 | M | Y | 0.00000 | 20160706 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125319251 | 12531925 | 1 | PS | NEURONTIN | GABAPENTIN | 1 | 600 MG, 3X/DAY | U | 20235 | 600 | MG | TID | |||||||
| 125319251 | 12531925 | 2 | SS | NEURONTIN | GABAPENTIN | 1 | U | 20235 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125319251 | 12531925 | 1 | Muscle spasms |
| 125319251 | 12531925 | 2 | Diabetic neuropathy |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125319251 | 12531925 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125319251 | 12531925 | Abnormal behaviour | |
| 125319251 | 12531925 | Dysstasia | |
| 125319251 | 12531925 | Product use issue | |
| 125319251 | 12531925 | Pyrexia | |
| 125319251 | 12531925 | Sepsis | |
| 125319251 | 12531925 | Speech disorder | |
| 125319251 | 12531925 | Toxicity to various agents |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |